University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
J Nucl Med. 2014 Jan;55(1):58-64. doi: 10.2967/jnumed.112.117515. Epub 2013 Nov 18.
Rubidium-ARMI ((82)Rb as an Alternative Radiopharmaceutical for Myocardial Imaging) is a multicenter trial to evaluate the accuracy, outcomes, and cost-effectiveness of low-dose (82)Rb perfusion imaging using 3-dimensional (3D) PET/CT technology. Standardized imaging protocols are essential to ensure consistent interpretation.
Cardiac phantom qualifying scans were obtained at 7 recruiting centers. Low-dose (10 MBq/kg) rest and pharmacologic stress (82)Rb PET scans were obtained in 25 patients at each site. Summed stress scores, summed rest scores, and summed difference scores (SSS, SRS, and SDS [respectively] = SSS-SRS) were evaluated using 17-segment visual interpretation with a discretized color map. All scans were coread at the core lab (University of Ottawa Heart Institute) to assess agreement of scoring, clinical diagnosis, and image quality. Scoring differences greater than 3 underwent a third review to improve consensus. Scoring agreement was evaluated with intraclass correlation coefficient (ICC-r), concordance of clinical interpretation, and image quality using κ coefficient and percentage agreement. Patient (99m)Tc and (201)Tl SPECT scans (n = 25) from 2 centers were analyzed similarly for comparison to (82)Rb.
Qualifying scores of SSS = 2, SDS = 2, were achieved uniformly at all imaging sites on 9 different 3D PET/CT scanners. Patient scores showed good agreement between core and recruiting sites: ICC-r = 0.92, 0.77 for SSS, SDS. Eighty-five and eighty-seven percent of SSS and SDS scores, respectively, had site-core differences of 3 or less. After consensus review, scoring agreement improved to ICC-r = 0.97, 0.96 for SSS, SDS (P < 0.05). The agreement of normal versus abnormal (SSS ≥ 4) and nonischemic versus ischemic (SDS ≥ 2) studies was excellent: ICC-r = 0.90 and 0.88. Overall interpretation showed excellent agreement, with a κ = 0.94. Image quality was perceived differently by the site versus core reviewers (90% vs. 76% good or better; P < 0.05). By comparison, scoring agreement of the SPECT scans was ICC-r = 0.82, 0.72 for SSS, SDS. Seventy-six and eighty-eight percent of SSS and SDS scores, respectively, had site-core differences of 3 or less. Consensus review again improved scoring agreement to ICC-r = 0.97, 0.90 for SSS, SDS (P < 0.05).
(82)Rb myocardial perfusion imaging protocols were implemented with highly repeatable interpretation in centers using 3D PET/CT technology, through an effective standardization and quality assurance program. Site scoring of (82)Rb PET myocardial perfusion imaging scans was found to be in good agreement with core lab standards, suggesting that the data from these centers may be combined for analysis of the rubidium-ARMI endpoints.
评估使用 3 维(3D)PET/CT 技术的低剂量(82)Rb 灌注成像的准确性、结果和成本效益。标准化的成像方案对于确保一致的解释至关重要。
在 7 个招募中心进行心脏模型合格扫描。在每个站点处对 25 名患者进行低剂量(10 MBq/kg)静息和药物负荷(82)Rb PET 扫描。使用 17 节段视觉解释和离散颜色图评估总和应激评分、总和静息评分和总和差异评分(SSS、SRS 和 SDS[分别] = SSS-SRS)。所有扫描均在核心实验室(渥太华心脏研究所)进行核心读取,以评估评分、临床诊断和图像质量的一致性。评分差异大于 3 分的进行第三次审查以提高共识。使用组内相关系数(ICC-r)、临床解释一致性和 κ 系数和百分比一致性评估评分一致性和图像质量。比较(82)Rb 对来自 2 个中心的 25 名患者(99m)Tc 和(201)Tl SPECT 扫描进行类似分析。
在所有 9 个不同的 3D PET/CT 扫描仪上,在所有成像部位均达到了统一的合格评分 SSS = 2、SDS = 2。患者评分显示核心和招募站点之间具有良好的一致性:ICC-r = 0.92、0.77 用于 SSS、SDS。分别有 85%和 87%的 SSS 和 SDS 评分的站点-核心差异为 3 或更小。在达成共识后,评分一致性提高到 ICC-r = 0.97、0.96 用于 SSS、SDS(P < 0.05)。正常与异常(SSS≥4)和非缺血与缺血(SDS≥2)研究的一致性非常好:ICC-r = 0.90 和 0.88。总体解释具有极好的一致性,κ = 0.94。站点与核心审查员对图像质量的看法不同(90%对 76%良好或更好;P < 0.05)。相比之下,SPECT 扫描的评分一致性为 ICC-r = 0.82、0.72 用于 SSS、SDS。分别有 76%和 88%的 SSS 和 SDS 评分的站点-核心差异为 3 或更小。共识审查再次提高了评分一致性,ICC-r = 0.97、0.90 用于 SSS、SDS(P < 0.05)。
(82)Rb 心肌灌注成像方案在使用 3D PET/CT 技术的中心得到了高度可重复的解释,通过有效的标准化和质量保证计划得以实施。(82)Rb PET 心肌灌注成像扫描的站点评分与核心实验室标准一致,表明这些中心的数据可以组合用于分析铷-ARMI 终点。